{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,30]],"date-time":"2026-07-30T22:39:38Z","timestamp":1785451178969,"version":"3.56.0"},"reference-count":29,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2009,12,3]],"date-time":"2009-12-03T00:00:00Z","timestamp":1259798400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/2.0\/"},{"start":{"date-parts":[[2009,12,3]],"date-time":"2009-12-03T00:00:00Z","timestamp":1259798400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/2.0\/"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Crit Care"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                        <jats:title>Introduction<\/jats:title>\n                        <jats:p>Renal insufficiency increases the half-life of low molecular weight heparins (LMWHs). Whether continuous venovenous hemofiltration (CVVH) removes LMWHs is unsettled. We studied hemostasis during nadroparin anticoagulation for CVVH, and explored the implication of the endogenous thrombin potential (ETP).<\/jats:p>\n                     <\/jats:sec><jats:sec>\n                        <jats:title>Methods<\/jats:title>\n                        <jats:p>This cross-over study, performed in a 20-bed teaching hospital ICU, randomized non-surgical patients with acute kidney injury requiring nadroparin for CVVH to compare hemostasis between two doses of CVVH: filtrate flow was initiated at 4 L\/h and converted to 2 L\/h after 60 min in group 1, and <jats:italic>vice versa<\/jats:italic> in group 2. Patients received nadroparin 2850 IU i.v., followed by 380 IU\/h continuously in the extracorporeal circuit. After baseline sampling, ultrafiltrate, arterial (art) and postfilter (PF) blood was taken for hemostatic markers after 1 h, and 15 min, 6 h, 12 h and 24 h after converting filtrate flow. We compared randomized groups, and 'early circuit clotting' to 'normal circuit life' groups.<\/jats:p>\n                     <\/jats:sec><jats:sec>\n                        <jats:title>Results<\/jats:title>\n                        <jats:p>Fourteen patients were randomized, seven to each group. Despite randomization, group 1 had higher SOFA scores (median 14 (IQR 11-15) versus 9 (IQR 5-9), p = 0.004). Anti-Xa <jats:sub>art<\/jats:sub> activity peaked upon nadroparin bolus and declined thereafter (p = 0.05). Anti-Xa <jats:sub>PF<\/jats:sub> did not change in time. Anti-Xa activity was not detected in ultrafiltrate. Medians of all anti-Xa samples were lower in group 1 (anti-Xa <jats:sub>art<\/jats:sub> 0.19 (0.12-0.37) vs. 0.31 (0.23-0.52), p = 0.02; anti-Xa <jats:sub>PF<\/jats:sub> 0.34 (0.25-0.44) vs. 0.51 (0.41-0.76), p = 0.005). After a steep decline, arterial ETP<jats:sub>AUC<\/jats:sub> tended to increase (p = 0.06), opposite to anti-Xa, while postfilter ETP<jats:sub>AUC<\/jats:sub> increased (p = 0.001). Median circuit life was 24.5 h (IQR 12-37 h). Patients with 'short circuit life' had longer baseline prothrombin time (PTT), activated thromboplastin time (aPTT), lower ETP, higher thrombin-antithrombin complexes (TAT) and higher SOFA scores; during CVVH, anti-Xa, and platelets were lower; PTT, aPTT, TAT and D-dimers were longer\/higher and ETP was slower and depressed.<\/jats:p>\n                     <\/jats:sec><jats:sec>\n                        <jats:title>Conclusions<\/jats:title>\n                        <jats:p>We found no accumulation and no removal of LMWH activity during CVVH. However, we found that early circuit clotting was associated with more severe organ failure, prior systemic thrombin generation with consumptive coagulopathy, heparin resistance and elevated extracorporeal thrombin generation. ETP integrates these complex effects on the capacity to form thrombin.<\/jats:p>\n                     <\/jats:sec><jats:sec>\n                        <jats:title>Trial registration<\/jats:title>\n                        <jats:p>Clinicaltrials.gov ID NCT00965328<\/jats:p>\n                     <\/jats:sec>","DOI":"10.1186\/cc8191","type":"journal-article","created":{"date-parts":[[2009,12,3]],"date-time":"2009-12-03T20:23:53Z","timestamp":1259871833000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":21,"title":["Hemostasis during low molecular weight heparin anticoagulation for continuous venovenous hemofiltration: a randomized cross-over trial comparing two hemofiltration rates"],"prefix":"10.1186","volume":"13","author":[{"given":"Heleen M","family":"Oudemans-van Straaten","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Muriel","family":"van Schilfgaarde","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pascal J","family":"Molenaar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jos PJ","family":"Wester","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anja","family":"Leyte","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2009,12,3]]},"reference":[{"key":"7617_CR1","doi-asserted-by":"publisher","first-page":"64S","DOI":"10.1378\/chest.119.1_suppl.64S","volume":"119","author":"J Hirsh","year":"2001","unstructured":"Hirsh J, Warkentin TE, Shaughnessy SG, Anand SS, Halperin JL, Raschke R, Granger C, Ohman EM, Dalen JE: Heparin and low-molecular-weight heparin: mechanisms of action, pharmacokinetics, dosing, monitoring, efficacy, and safety.\n                           Chest 2001, 119: 64S-94S. 10.1378\/chest.119.1_suppl.64S","journal-title":"Chest"},{"key":"7617_CR2","doi-asserted-by":"crossref","first-page":"1162","DOI":"10.1055\/s-0037-1615034","volume":"79","author":"P Mismetti","year":"1998","unstructured":"Mismetti P, Laporte-Simitsidis S, Navarro C, Sie P, d'Azemar P, Necciari J, Duret JP, Gaud C, Decousus H, Boneu B: Aging and venous thromboembolism influence the pharmacodynamics of the anti-factor Xa and anti-thrombin activities of a low molecular weight heparin (nadroparin).\n                           Thromb Haemost 1998, 79: 1162-1165.","journal-title":"Thromb Haemost"},{"key":"7617_CR3","doi-asserted-by":"publisher","first-page":"673","DOI":"10.7326\/0003-4819-144-9-200605020-00011","volume":"144","author":"W Lim","year":"2006","unstructured":"Lim W, Dentali F, Eikelboom JW, Crowther MA: Meta-analysis: low-molecular-weight heparin and bleeding in patients with severe renal insufficiency.\n                           Ann Intern Med 2006, 144: 673-684.","journal-title":"Ann Intern Med"},{"key":"7617_CR4","doi-asserted-by":"publisher","first-page":"212","DOI":"10.1007\/BF01704703","volume":"20","author":"M Singer","year":"1994","unstructured":"Singer M, McNally T, Screaton G, Mackie I, Machin S, Cohen SL: Heparin clearance during continuous veno-venous haemofiltration.\n                           Intensive Care Med 1994, 20: 212-215. 10.1007\/BF01704703","journal-title":"Intensive Care Med"},{"key":"7617_CR5","doi-asserted-by":"publisher","first-page":"1444","DOI":"10.1016\/j.clinthera.2005.09.008","volume":"27","author":"A Isla","year":"2005","unstructured":"Isla A, Gascon AR, Maynar J, Arzuaga A, Corral E, Martin A, Solinis MA, Munoz JL: In vitro and in vivo evaluation of enoxaparin removal by continuous renal replacement therapies with acrylonitrile and polysulfone membranes.\n                           Clin Ther 2005, 27: 1444-1451. 10.1016\/j.clinthera.2005.09.008","journal-title":"Clin Ther"},{"key":"7617_CR6","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1160\/TH06-07-0408","volume":"96","author":"HC Hemker","year":"2006","unstructured":"Hemker HC, Al Dieri R, De Smedt E, Beguin S: Thrombin generation, a function test of the haemostatic-thrombotic system.\n                           Thromb Haemost 2006, 96: 553-561.","journal-title":"Thromb Haemost"},{"key":"7617_CR7","unstructured":"Nationale Intensive Care Evaluatie[http:\/\/www.stichting-nice.nl]"},{"key":"7617_CR8","doi-asserted-by":"publisher","first-page":"818","DOI":"10.1097\/00003246-198510000-00009","volume":"13","author":"WA Knaus","year":"1985","unstructured":"Knaus WA, Draper EA, Wagner DP, Zimmerman JE: APACHE II: a severity of disease classification system.\n                           Crit Care Med 1985, 13: 818-829. 10.1097\/00003246-198510000-00009","journal-title":"Crit Care Med"},{"key":"7617_CR9","doi-asserted-by":"publisher","first-page":"1619","DOI":"10.1378\/chest.100.6.1619","volume":"100","author":"WA Knaus","year":"1991","unstructured":"Knaus WA, Wagner DP, Draper EA, Zimmerman JE, Bergner M, Bastos PG, Sirio CA, Murphy DJ, Lotring T, Damiano A: The APACHE III prognostic system. Risk prediction of hospital mortality for critically ill hospitalized adults.\n                           Chest 1991, 100: 1619-1636. 10.1378\/chest.100.6.1619","journal-title":"Chest"},{"key":"7617_CR10","doi-asserted-by":"publisher","first-page":"2957","DOI":"10.1001\/jama.1993.03510240069035","volume":"270","author":"JR Le Gall","year":"1993","unstructured":"Le Gall JR, Lemeshow S, Saulnier F: A new Simplified Acute Physiology Score (SAPS II) based on a European\/North American multicenter study.\n                           JAMA 1993, 270: 2957-2963. 10.1001\/jama.270.24.2957","journal-title":"JAMA"},{"key":"7617_CR11","doi-asserted-by":"publisher","first-page":"707","DOI":"10.1007\/BF01709751","volume":"22","author":"JL Vincent","year":"1996","unstructured":"Vincent JL, Moreno R, Takala J, Willatts S, de Mendonca A, Bruining H, Reinhart CK, Suter PM, Thijs LG: The SOFA (Sepsis-related Organ Failure Assessment) score to describe organ dysfunction\/failure. On behalf of the Working Group on Sepsis-Related Problems of the European Society of Intensive Care Medicine.\n                           Intensive Care Med 1996, 22: 707-710. 10.1007\/BF01709751","journal-title":"Intensive Care Med"},{"key":"7617_CR12","doi-asserted-by":"publisher","first-page":"R204","DOI":"10.1186\/cc2872","volume":"8","author":"R Bellomo","year":"2004","unstructured":"Bellomo R, Ronco C, Kellum JA, Mehta RL, Palevsky P: Acute renal failure - definition, outcome measures, animal models, fluid therapy and information technology needs: the Second International Consensus Conference of the Acute Dialysis Quality Initiative (ADQI) Group.\n                           Crit Care 2004, 8: R204-R212. 10.1186\/cc2872","journal-title":"Crit Care"},{"key":"7617_CR13","doi-asserted-by":"publisher","first-page":"1571","DOI":"10.1007\/s00134-007-0719-7","volume":"33","author":"M Joannidis","year":"2007","unstructured":"Joannidis M, Kountchev J, Rauchenzauner M, Schusterschitz N, Ulmer H, Mayr A, Bellmann R: Enoxaparin vs. unfractionated heparin for anticoagulation during continuous veno-venous hemofiltration: a randomized controlled crossover study.\n                           Intensive Care Med 2007, 33: 1571-1579. 10.1007\/s00134-007-0719-7","journal-title":"Intensive Care Med"},{"key":"7617_CR14","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1093\/ndt\/18.2.252","volume":"18","author":"J Chanard","year":"2003","unstructured":"Chanard J, Lavaud S, Randoux C, Rieu P: New insights in dialysis membrane biocompatibility: relevance of adsorption properties and heparin binding.\n                           Nephrol Dial Transplant 2003, 18: 252-257. 10.1093\/ndt\/18.2.252","journal-title":"Nephrol Dial Transplant"},{"key":"7617_CR15","doi-asserted-by":"publisher","first-page":"R45","DOI":"10.1186\/cc4853","volume":"10","author":"D Cheyron du","year":"2006","unstructured":"Cheyron du D, Bouchet B, Bruel C, Daubin C, Ramakers M, Charbonneau P: Antithrombin supplementation for anticoagulation during continuous hemofiltration in critically ill patients with septic shock: a case-control study.\n                           Crit Care 2006, 10: R45. 10.1186\/cc4853","journal-title":"Crit Care"},{"key":"7617_CR16","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1097\/MAT.0b013e31815cc3bf","volume":"54","author":"M Lafargue","year":"2008","unstructured":"Lafargue M, Joannes-Boyau O, Honore PM, Gauche B, Grand H, Fleureau C, Roze H, Janvier G: Acquired deficit of antithrombin and role of supplementation in septic patients during continuous veno-venous hemofiltration.\n                           ASAIO J 2008, 54: 124-128. 10.1097\/MAT.0b013e31815cc3bf","journal-title":"ASAIO J"},{"key":"7617_CR17","doi-asserted-by":"publisher","first-page":"649","DOI":"10.1016\/S0022-2143(97)90115-3","volume":"130","author":"L Manson","year":"1997","unstructured":"Manson L, Weitz JI, Podor TJ, Hirsh J, Young E: The variable anticoagulant response to unfractionated heparin in vivo reflects binding to plasma proteins rather than clearance.\n                           J Lab Clin Med 1997, 130: 649-655. 10.1016\/S0022-2143(97)90115-3","journal-title":"J Lab Clin Med"},{"key":"7617_CR18","doi-asserted-by":"publisher","first-page":"25856","DOI":"10.1074\/jbc.272.41.25856","volume":"272","author":"S Liu","year":"1997","unstructured":"Liu S, Hoke D, Julian J, Carson DD: Heparin\/heparan sulfate (HP\/HS) interacting protein (HIP) supports cell attachment and selective, high affinity binding of HP\/HS.\n                           J Biol Chem 1997, 272: 25856-25862. 10.1074\/jbc.272.41.25856","journal-title":"J Biol Chem"},{"key":"7617_CR19","doi-asserted-by":"publisher","first-page":"1568","DOI":"10.1161\/01.ATV.17.8.1568","volume":"17","author":"E Young","year":"1997","unstructured":"Young E, Podor TJ, Venner T, Hirsh J: Induction of the acute-phase reaction increases heparin-binding proteins in plasma.\n                           Arterioscler Thromb Vasc Biol 1997, 17: 1568-1574.","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"7617_CR20","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1160\/TH07-06-0424","volume":"99","author":"H Hochart","year":"2008","unstructured":"Hochart H, Jenkins PV, Preston RJ, Smith OP, White B, O'Donnell J: Concentration-dependent roles for heparin in modifying lipopolysaccharide-induced activation of mononuclear cells in whole blood.\n                           Thromb Haemost 2008, 99: 570-575.","journal-title":"Thromb Haemost"},{"key":"7617_CR21","doi-asserted-by":"publisher","first-page":"2221","DOI":"10.1182\/blood.V99.6.2221","volume":"99","author":"MA Gebska","year":"2002","unstructured":"Gebska MA, Titley I, Paterson HF, Morilla RM, Davies DC, Gruszka-Westwood AM, Kakkar VV, Eccles S, Scully MF: High-affinity binding sites for heparin generated on leukocytes during apoptosis arise from nuclear structures segregated during cell death.\n                           Blood 2002, 99: 2221-2227. 10.1182\/blood.V99.6.2221","journal-title":"Blood"},{"key":"7617_CR22","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1002\/path.2274","volume":"214","author":"S Sriskandan","year":"2008","unstructured":"Sriskandan S, Altmann DM: The immunology of sepsis.\n                           J Pathol 2008, 214: 211-223. 10.1002\/path.2274","journal-title":"J Pathol"},{"key":"7617_CR23","doi-asserted-by":"publisher","first-page":"R93","DOI":"10.1186\/cc4952","volume":"10","author":"MK Rommers","year":"2006","unstructured":"Rommers MK, Van der LN, Egberts TC, Bemt PM: Anti-Xa activity after subcutaneous administration of dalteparin in ICU patients with and without subcutaneous oedema: a pilot study.\n                           Crit Care 2006, 10: R93. 10.1186\/cc4952","journal-title":"Crit Care"},{"key":"7617_CR24","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1016\/S0049-3848(02)00028-2","volume":"105","author":"AJ Mayr","year":"2002","unstructured":"Mayr AJ, Dunser M, Jochberger S, Fries D, Klingler A, Joannidis M, Hasibeder W, Schobersberger W: Antifactor Xa activity in intensive care patients receiving thromboembolic prophylaxis with standard doses of enoxaparin.\n                           Thromb Res 2002, 105: 201-204. 10.1016\/S0049-3848(02)00028-2","journal-title":"Thromb Res"},{"key":"7617_CR25","doi-asserted-by":"publisher","first-page":"1405","DOI":"10.1097\/01.CCM.0000059725.60509.A0","volume":"31","author":"U Priglinger","year":"2003","unstructured":"Priglinger U, Delle KG, Geppert A, Joukhadar C, Graf S, Berger R, Hulsmann M, Spitzauer S, Pabinger I, Heinz G: Prophylactic anticoagulation with enoxaparin: Is the subcutaneous route appropriate in the critically ill?\n                           Crit Care Med 2003, 31: 1405-1409. 10.1097\/01.CCM.0000059725.60509.A0","journal-title":"Crit Care Med"},{"key":"7617_CR26","doi-asserted-by":"publisher","first-page":"849","DOI":"10.1016\/S0140-6736(02)07920-5","volume":"359","author":"J Dorffler-Melly","year":"2002","unstructured":"Dorffler-Melly J, de Jonge E, Pont AC, Meijers J, Vroom MB, Buller HR, Levi M: Bioavailability of subcutaneous low-molecular-weight heparin to patients on vasopressors.\n                           Lancet 2002, 359: 849-850. 10.1016\/S0140-6736(02)07920-5","journal-title":"Lancet"},{"key":"7617_CR27","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1159\/000102050","volume":"35","author":"LF Lincz","year":"2006","unstructured":"Lincz LF, Lonergan A, Scorgie FE, Rowlings P, Gibson R, Lawrie A, Seldon M: Endogenous thrombin potential for predicting risk of venous thromboembolism in carriers of factor V Leiden.\n                           Pathophysiol Haemost Thromb 2006, 35: 435-439. 10.1159\/000102050","journal-title":"Pathophysiol Haemost Thromb"},{"key":"7617_CR28","doi-asserted-by":"publisher","first-page":"565","DOI":"10.1016\/j.thromres.2008.03.017","volume":"123","author":"JW Seo","year":"2009","unstructured":"Seo JW, Kim HK, Kim JE, Park S, Cho HI: Prognostic values of the factor Xa-activated clotting time and endogenous thrombin potential in patients suspected of having disseminated intravascular coagulation.\n                           Thromb Res 2009, 123: 565-572. 10.1016\/j.thromres.2008.03.017","journal-title":"Thromb Res"},{"key":"7617_CR29","doi-asserted-by":"publisher","first-page":"545","DOI":"10.1097\/CCM.0b013e3181953c5e","volume":"37","author":"HM Oudemans-Van Straaten","year":"2009","unstructured":"Oudemans-Van Straaten HM, Bosman RJ, Koopmans M, Voort PH, Wester JP, Spoel JI, Dijksman LM, Zandstra DF: Citrate anticoagulation for continuous venovenous hemofiltration.\n                           Crit Care Med 2009, 37: 545-552. 10.1097\/CCM.0b013e3181953c5e","journal-title":"Crit Care Med"}],"container-title":["Critical Care"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/cc8191.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/cc8191\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/cc8191.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,7]],"date-time":"2024-10-07T12:48:18Z","timestamp":1728305298000},"score":1,"resource":{"primary":{"URL":"https:\/\/ccforum.biomedcentral.com\/articles\/10.1186\/cc8191"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,12,3]]},"references-count":29,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2009,12]]}},"alternative-id":["7617"],"URL":"https:\/\/doi.org\/10.1186\/cc8191","relation":{},"ISSN":["1364-8535"],"issn-type":[{"value":"1364-8535","type":"electronic"}],"subject":[],"published":{"date-parts":[[2009,12,3]]},"assertion":[{"value":"6 August 2009","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 October 2009","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 December 2009","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 December 2009","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}],"article-number":"R193"}}